Who are Altesa BioSciences's investors?

Altesa BioSciences's investors include GRA Venture, Forbion, Medicxi, Pitango, Sanofi Ventures.

How much funding has Altesa BioSciences raised?

Altesa BioSciences has disclosed $110M raised across 2 rounds.

Where is Altesa BioSciences headquartered?

Altesa BioSciences is headquartered in College Park, US.

Altesa BioSciences

College Park, US · Founded 2020 · Delaware corporation · 6 known investors

Find your way into Altesa BioSciences

218 people in our graph share verified history with the Altesa BioSciences team — schools, employers, funds. One of them is your warm intro.

Jesse Blandunlockedknows John Clerici · together at McKenna Long & Aldridge LLP (overlapped)

×2knows the team · via McKenna Long & Aldridge LLP

×9knows the team · via United States Air Force

Altesa BioSciences is a clinical-stage pharmaceutical company developing vapendavir, an orally administered antiviral targeting rhinovirus infections in patients with chronic lung diseases such as COPD and asthma. The drug aims to stop viral infections before they trigger acute respiratory exacerbations, addressing the underlying viral cause rather than downstream inflammation.

Biotech Healthtech

Founders & leadership

John Clerici Chief Operating OfficerJohn Clerici is Chief Operating Officer of Altesa BioSciences, a clinical-stage pharmaceutical company developing an antiviral for rhinovirus infections in patients with chronic lung diseases. He holds a law degree from the University of North Carolina at Chapel Hill and has over two decades of experience in public health preparedness and biotechnology funding, including work on federal countermeasure programs and pandemic response legislation.

Andrew DrechslerExecutive

Brett GiroirExecutive

Board

Nicholas WilliamsBoard directorInvestor at Medicxi

Moncef SlaouiBoard directorInvestor at Medicxi

Jon Edwards Board MemberGeneral Partner at Forbion

Ittai Harel Director Board of DirectorsManaging Partner | HealthTech at Pitango

Seth RudnickBoard directorVenture Partner at Pitango

Investors · 6

GRA Venturelisted by GRA VentureGeorgia

ForbionreportedNaarden

How we know: funding news · prnewswire.com · Not right? Tell us

MedicxireportedLondonvia Moncef Slaoui · board

How we know: board seat on SEC Form D · funding news · prnewswire.com · Not right? Tell us

PitangoreportedTel Aviv · $4M – $100Mvia Ittai Harel · board

How we know: board seat on SEC Form D · funding news · prnewswire.com · Not right? Tell us

Sanofi VenturesreportedCambridge · $5M

How we know: prnewswire.com · Not right? Tell us

Also in the syndicate · 1

Atlantic Partners

Reported raises · per SEC filings

Form D private placements

$110M disclosed across 2 rounds · 2022–2026

▶$75MraisedFeb 2026 · 17 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

John ClericiExecutive Officer
Nicholas WilliamsDirector
Moncef SlaouiDirector
Andrew DrechslerExecutive Officer
Seth RudnickDirector
Jon EdwardsDirector
Brett GiroirExecutive Officer, Director
Ittai HarelDirector

Offering amount: $75M
Amount sold: $75M
First sale: Feb 2026
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$35MraisedJul 2023 · 18 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Brett GiroirExecutive Officer, Director
Ittai HarelDirector
Moncef SlaouiDirector
Seth RudnickDirector
Nicholas WilliamsDirector
John ClericiExecutive Officer

Offering amount: $35M
Amount sold: $35M
First sale: Dec 2022
Incorporated: Corporation, Delaware, 2020
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

Atropos HealthAtropos Health develops a cloud-based platform that generates real-world evidence from electronic health records to inform clinical decision-making and healthcare research. The company enables healthcare institutions, clinicians, and life sciences organizations to rapidly conduct observational studies from patient data for personalized medicine and evidence-based practice.

AlestaAlesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology. The biotech company works on early-stage drug development and clinical research.

Companies working in the same space as Altesa BioSciences.

In the news

Altesa BioSciences Raises $75M in Series B Fundingfinsmes.com · Feb 2026

Altesa BioSciences Closes Oversubscribed $75 Million Series B Financing to Transform Treatment of Chronic Lung Diseasesprnewswire.com · Feb 2026

Frequently asked questions

What does Altesa BioSciences do?: Altesa BioSciences is a clinical-stage pharmaceutical company developing vapendavir, an orally administered antiviral targeting rhinovirus infections in patients with chronic lung diseases such as COPD and asthma. The drug aims to stop viral infections before they trigger acute respiratory exacerbations, addressing the underlying viral cause rather than downstream inflammation.
Who are Altesa BioSciences's investors?: Altesa BioSciences's investors include GRA Venture, Forbion, Medicxi, Pitango, Sanofi Ventures.
How much funding has Altesa BioSciences raised?: Altesa BioSciences has disclosed $110M raised across 2 rounds.
Where is Altesa BioSciences headquartered?: Altesa BioSciences is headquartered in College Park, US.